¹**Arterial hypertension and** β**-amyloid accumulation have** ²**spatially overlapping effects on posterior white matter**

³**hyperintensity volume: A cross-sectional study**

4 Jose Bernal^{1,2, T}, Stefanie Schreiber^{2,3, T}, Inga Menze^{1,2}, Anna Ostendorf¹, Malte Pfister³, Jonas 5 Geisendörfer³, Aditya Nemali^{1,2}, Anne Maass², Renat Yakupov², Oliver Peters^{4,5}, Lukas 6 Preis⁵, Luisa Schneider⁵, Ana Lucia Herrera⁵, Josef Priller^{4,6,7,8}, Eike Jakob Spruth^{4,6}, Slawek 7 Altenstein^{4,6}, Anja Schneider^{9,10}, Klaus Fliessbach^{9,10}, Jens Wiltfang^{11,12,13}, Björn 8 H.Schott^{11,12}, Ayda Rostamzadeh¹⁴, Wenzel Glanz¹, Katharina Buerger^{16,17}, Daniel 9 Janowitz¹⁷, Michael Ewers^{16,17}, Robert Perneczky^{18,19,20,21,33}, Boris-Stephan Rauchmann¹⁹, 10 Stefan Teipel^{22,23}, Ingo Kilimann^{22,23}, Christoph Laske^{24,25}, Matthias H. Munk^{24,26}, Annika 11 Spottke^{9,10}, Nina Roy⁹, Laura Dobisch², Peter Dechent²⁷, Klaus Scheffler²⁸, Stefan Hetzer²⁹, 12 Steffen Wolfsgruber^{9,10}, Luca Kleineidam^{9,10}, Matthias Schmid^{9, 30}, Moritz Berger³⁰, Frank 13 Jessen^{9,14,15}, Miranka Wirth³¹, Emrah Düzel^{1,2,32,†}, Gabriel Ziegler^{1,2,†}

- ^Τ 14 **Shared first authorship**
- **†** 15 **Shared last authorship**

16 **Author affiliations:**

- ¹ Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University
- 18 Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany
- ² 19 ² German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44,
- 20 39120 Magdeburg, Germany
- ³ Department of Neurology, University Hospital Magdeburg, Medical Faculty, Leipziger Str.
- 22 44, 39120 Magdeburg, Germany

- 24 ⁵ Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and
- 25 Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany
- ⁶ 26 Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 Berlin,

27 Germany

- 28 ⁷ School of Medicine, Technical University of Munich; Department of Psychiatry and
- 29 Psychotherapy, Munich, Germany
- 30 ⁸University of Edinburgh and UK DRI, Edinburgh, UK
- ⁹ 31 ⁹ German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 32 53127 Bonn, Germany
- ¹⁰ University of Bonn Medical Center, Dept. of Neurodegenerative Disease and Geriatric
- 34 Psychiatry/Psychiatry, Venusberg-Campus 1, 53127 Bonn, Germany
- ¹¹ German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
- 12 $\text{Department of Psychiatry}$ and Psychotherapy, University Medical Center Goettingen,
- 37 University of Goettingen, Von-Siebold-Str. 5, 37075 Goettingen
- ¹³ Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of
- 39 Medical Sciences, University of Aveiro, Aveiro, Portugal
- 140 ¹⁴ Department of Psychiatry, University of Cologne, Medical Faculty, Kerpener Strasse 62,
- 41 50924 Cologne, Germany
- ¹⁵ Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD),
- 43 University of Cologne, Joseph-Stelzmann-Strasse 26, 50931 Köln, Germany

- ¹⁶ German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse
- 45 17, 81377 Munich, Germany
- 17 Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich,
- 47 Feodor-Lynen-Strasse 17, 81377 Munich, Germany
- ¹⁸ German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse
- 49 17, 81377 Munich, Germany
- ¹⁹ Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich,
- 51 Germany
- 2^{20} Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany
- 2^{1} Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College
- 54 London, London, UK
- 2^{22} German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
- ²³ Department of Psychosomatic Medicine, Rostock University Medical Center, Gehlsheimer
- 57 Str. 20, 18147 Rostock
- 2^{24} German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
- ²⁵ Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department
- 60 of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
- 26 \degree Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
- 62 ²⁷ MR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-
- 63 University Goettingen, Germany
- 2^{28} Department for Biomedical Magnetic Resonance, University of Tübingen, 72076 Tübingen,
- 65 Germany

- 67 Germany
- ³⁰ Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn,
- 69 Venusberg-Campus 1, D-53127 Bonn
- ³¹ German Center for Neurodegenerative Diseases (DZNE), Dresden, Tatzberg 41, 01307
- 71 Dresden, Germany
- ³² Institute of Cognitive Neuroscience, University College London, London, UK
- ³³ 73 Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield,
- 74 Sheffield, UK

75

- 76 Correspondence to: Jose Bernal & Miranka Wirth
- 77 Full address: German Centre for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger
- 78 Str. 44, 39120 Magdeburg, Germany & German Centre for Neurodegenerative Diseases
- 79 (DZNE), Dresden, Tatzberg 41, 01307 Dresden, Germany
- 80 E-mail: jose.bernalmoyano@dzne.de & miranka.wirth@dzne.de

⁸¹**Abbreviations**

- 82 A^β ^β-amyloid
- 83 AD Alzheimer's disease
- 84 ATN Amyloid/Tau/Neurodegeneration
- 85 B regression coefficient

- 86 CAA Cerebral amyloid angiopathy
- 87 CERAD Consortium to Establish a Registry for Alzheimer's Disease
- 88 CN Non-complaining healthy controls
- 89 CSF Cerebrospinal fluid
- 90 CSVD Cerebral small vessel disease
- 91 FDR False discovery rate
- 92 FLAIR Fluid Attenuated Inversion Recovery
- 93 GM Grey matter
- 94 IQR Interquartile range
- 95 MCI Mild cognitive impairment
- 96 MRI Magnetic resonance imaging
- 97 NC Normal cognition
- 98 PACC5 Preclinical Alzheimer's Cognitive Composite 5
- 99 ROI Region of interest
- 100 SCD Subjective cognitive decline
- 101 SD Standard deviation
- 102 SE Standard error
- 103 SPM Statistical parametric mapping
- 104 TICV Total intracranial volume
- 105 WM White matter

106 WMH White matter hyperintensities

¹⁰⁷**Abstract**

108 **Background**

109 Posterior white matter hyperintensities (WMH) in subjects across the Alzheimer's disease 110 (AD) spectrum with minimal vascular pathology suggests that amyloid pathology—not just 111 arterial hypertension—impacts WMH, adversely influencing cognition. Here we seek to 112 determine the effect of both hypertension and Aβ positivity on WMH, and their impact on 113 cognition.

114 **Methods**

115 We analysed data from subjects with a low vascular profile and normal cognition (NC), 116 subjective cognitive decline (SCD), and amnestic mild cognitive impairment (MCI) enrolled 117 in the ongoing observational multicentre DZNE Longitudinal Cognitive Impairment and 118 Dementia Study (n=375, median age 70.2 [IQR 66.0-74.4] years; 176 female; NC/SCD/MCI 119 127/162/86). All subjects underwent a rich neuropsychological assessment. We focused on 120 baseline memory and executive function—derived from multiple neuropsychological tests 121 using confirmatory factor analysis—, baseline preclinical Alzheimer's cognitive composite 5 122 (PACC5) scores, and changes in PACC5 scores over course of three years (ΔPACC5).

123 **Results**

124 Subjects with hypertension or Aβ positivity presented the largest WMH volumes 125 (*pFDR*<0.05), with spatial overlap in the frontal (hypertension: 0.42±0.17; Aβ: 0.46±0.18), 126 occipital (hypertension: 0.50±0.16; Aβ: 0.50±0.16), parietal lobes (hypertension: 0.57±0.18;

127 Aβ: 0.56±0.20), corona radiata (hypertension: 0.45±0.17; Aβ: 0.40±0.13), optic radiation

128 (hypertension: 0.39±0.18; Aβ: 0.74±0.19), and splenium of the corpus callosum 129 (hypertension: 0.36±0.12; Aβ: 0.28±0.12). Hypertension, Aβ positivity, and WMH were 130 connected to cognition. First, WMH coincided with worse cognitive performance and 131 outcomes (*p_{FDR}*<0.05), regardless of Aβ and hypertension. Accelerated cognitive decline was 132 associated with WMH in the genu of the corpus callosum and segments of the forceps major 133 and inferior fronto-occipital longitudinal fasciculus (p_{FDR} <0.05). Second, hypertension was 134 indirectly linked to cognitive performance at baseline and over time via splenial WMH 135 (*indirect-only effect*; memory: -0.05±0.02, *pFDR*=0.029; executive: -0.04±0.02, *pFDR*=0.067; 136 PACC5: -0.05±0.02, *pFDR*=0.030; ΔPACC5: -0.09±0.03, *pFDR*=0.043). Third, the relationship 137 between Aβ positivity and baseline and longitudinal cognitive performance was independent 138 of WMH burden.

139 **Conclusions**

140 Posterior white matter is susceptible to hypertension and Aβ accumulation and it mediates the 141 association between hypertension and cognitive dysfunction. Posterior WMH could be a 142 promising target to tackle the downstream damage related to the potentially interacting and 143 potentiating effects of the two pathologies.

144 **Trial Registration**

145 German Clinical Trials Register (DRKS00007966, 04/05/2015)

146

147 **Keywords:** white matter hyperintensities; vascular risk; Alzheimer's disease; cognitive 148 performance; MRI

¹⁴⁹**Background**

150 The term "cerebral white matter hyperintensities" (WMH) describes dynamic and diffuse 151 microstructural alterations in both periventricular and deep white matter, which appear 152 hypodense on computed tomography and hyperintense on T2-weighted magnetic resonance 153 imaging (MRI) and coincide with demyelination, axon loss, and gliosis [1,2]. WMH are 154 common—especially but not exclusively in old age—and relate to a large spectrum of 155 clinical symptoms, including apathy, fatigue, delirium, depression, progressive cognitive 156 impairment, physical function disturbances, and increased risk of dementia and stroke [2,3].

157 Alterations to the functioning of cerebral micro-vessels—also known as cerebral small vessel 158 disease (CSVD)—caused, for instance, by long-term exposure to cardiovascular risk factors 159 (hypertension particularly) have been assumed to drive WMH formation [4–6]. Nonetheless, 160 recent studies demonstrating elevated global and posterior WMH in patients along the 161 Alzheimer's disease (AD) spectrum with minimal vascular pathology (for review see [1,7–9]) 162 call into question the assumption that any "AD-related" WMH solely reflect a vascular 163 contribution. This viewpoint has also been challenged by studies reporting a more "AD-like" 164 WMH pattern in Aβ positive subjective cognitive decline (SCD), mild cognitive impairment 165 (MCI) or AD. The "AD-like" pattern is roughly confined to deep and periventricular posterior 166 regions comprising the (parieto-)occipital lobe, corona radiata, optic (thalamic) radiation, or 167 the corpus callosum (especially splenium) and presents neuropathologically with underlying 168 gliosis, and axonal and myelin loss, but minimal vascular pathology—likely occurring 169 secondary to cortical neurodegeneration [7–10]. Further studies demonstrate frontal or 170 temporoparietal WMH dominance in AD as well and others report mixed results on the 171 relationship between posterior WMH and AD pathology [11–14]. "WMH of presumed

172 vascular origin" are, however, usually depicted in deep and periventricular frontal areas,

173 suggesting some spatial WMH heterogeneity in hypertension compared to AD [8,15].

174 Here we use region- and voxel-based lesion analysis to determine the effect of both 175 hypertension and AD pathology, i.e. β-amyloid (Aβ) positivity, on WMH as well as their 176 interacting impact on cognition. For that purpose, we study WMH of non-demented 177 participants of a large multicentre cohort with available cerebrospinal fluid (CSF) AD 178 biomarkers, history of hypertension, and cross-sectional as well as longitudinal 179 neuropsychological tests.

¹⁸⁰**Methods**

181 **Study design**

182 We used baseline MRI, CSF AD biomarkers, cognitive performance scores, medical records 183 and longitudinal cognitive performance scores from the DELCODE (DZNE Longitudinal 184 Cognitive Impairment and Dementia Study) cohort, an observational multicentre study from 185 the German Centre for Neurodegenerative Diseases (DZNE) that focuses on the multimodal 186 assessment of preclinical and clinical AD stages [16]. All participants received an extensive 187 assessment at the local study site prior to joining DELCODE, which included medical 188 history, psychiatric and neurological examination, neuropsychological testing, blood 189 laboratory work-up, and routine MRI in accordance with local standards. All memory clinics 190 used the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) 191 neuropsychological test battery [17] to assess cognitive function. We focused on non-192 complaining healthy controls with normal cognition (NC) and participants with SCD and

193 MCI and excluded patients with dementia due to AD to enrich our sample by variance due to 194 vascular disease and Aβ pathology.

195 The presence of SCD and amnestic MCI was diagnosed using the existing research criteria 196 for SCD [18,19] and MCI [20], respectively. Participants were diagnosed with SCD if they 197 reported subjective cognitive decline or memory concerns, as expressed to the physician of 198 the memory centre, and had a test performance better than -1.5 standard deviations (SD) 199 below the age, sex, and education-adjusted normal performance on all subtests of the 200 CERAD battery. The MCI group consisted of participants with amnestic MCI, as defined by 201 age, sex, and education-adjusted performance below -1.5 SD on the delayed recall trial of the 202 CERAD word-list episodic memory tests.

203 The NC group was recruited through local newspaper advertisements. Individuals who 204 responded to the advertisement were screened by telephone with regard to SCD. The control 205 group had to achieve unimpaired cognitive performance according to the same definition as 206 the SCD group.

207 All participants entered DELCODE based on either their clinical diagnosis derived from the 208 clinical workup or their identification as a control subject according to the procedures 209 outlined. Additional inclusion criteria for all groups were age □ ≥ □ 60 years, fluent German 210 language skills, capacity to provide informed consent, and presence of a study partner. The 211 main exclusion criteria for all groups were conditions clearly interfering with participation in 212 the study or the study procedures, including significant sensory impairment. The following 213 medical conditions were considered exclusion criteria: current major depressive episode, 214 major psychiatric disorders either at baseline or in the past (e.g., psychotic disorder, bipolar 215 disorder, substance abuse), neurodegenerative disorder other than AD, vascular dementia, 216 history of stroke with residual clinical symptoms, history of malignant disease, severe or

217 unstable medical conditions, and clinically significant laboratory abnormalities in vitamin 218 B12. Prohibited drugs included chronic use of psychoactive compounds with sedative or 219 anticholinergic effects, use of anti-dementia agents in SCD, amnestic MCI, and control 220 subjects, and investigational drugs for the treatment of dementia or cognitive impairment one 221 month before entry and throughout the duration of the study.

222 All participants gave written informed consent before inclusion in the study. DELCODE is

223 retrospectively registered at the German Clinical Trials Register (DRKS00007966,

224 04/05/2015) and was approved by ethical committees and local review boards.

225 **Hypertension**

226 Medical records were retrospectively screened for cardiovascular risk factors at the time of 227 MRI. Patients diagnosed before to have primary or secondary arterial hypertension were 228 considered to suffer from arterial hypertension (1: hypertensive; 0: normotensive). Single 229 blood pressure measurements were not taken into account since repeated, long-term or at-230 home measurements would be required for the final diagnosis [21].

231 **Cognitive performance**

232 All participants underwent a rich neuropsychological assessment, comprising the Mini-233 Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale–Cognitive 13- 234 item subscale (ADAS-Cog 13), the Free and Cued Selective Reminding Test (FCRST; 235 including a serial subtraction task, Wechsler Memory Scale revised version (WMS-R), 236 Logical Memory [Story A] and Digit Span), two semantic fluency tasks (animals and 237 groceries), the Boston Naming Test (15-item short version analogue to the CERAD battery, 238 supplemented by five infrequent items from the long version), the oral form of the Symbol-239 Digit-Modalities Test (including a subsequent free recall of symbols and symbol-digit

240 pairings), Trail Making Test Parts A and B, Clock Drawing and Clock Copying, a recall task 241 of previously copied figures (as in the CERAD test battery), the Face Name Associative 242 Recognition Test, and a Flanker task to assess executive control of attention. We focused on 243 memory and executive function at baseline derived from these neuropsychological tests using 244 confirmatory factor analysis to reduce the influence of test-specific effects and measurement 245 errors [22].

246 We also leveraged the Preclinical Alzheimer's Disease Cognitive Composite (PACC5) [23], 247 which provides a single outcome measure reflective of episodic memory, timed executive 248 function, and global cognition; domains that have been found sensitive to amyloid pathology. 249 The PACC5 score was calculated as the mean of an individual's z-standardised performance 250 in the FCSRT Free Recall and Total Recall, the MMSE, the WMS-R Logical Memory Story 251 A Delayed Recall, the Symbol-Digit-Modalities Test, and the sum of the two category 252 fluency tasks and used the baseline mean and SD values of the cognitively unimpaired group 253 of our sample to derive the subtest z-scores.

254 We selected subjects with available PACC5 scores over three annual follow-ups for further 255 analysis. We estimated rates of change in these PACC5 scores over time using a linear mixed 256 effect model (\triangle PACC5 from hereon). We expressed it as follows:

$$
PACC5_{ij} = X_{ij}\beta + Z_{ij}b_i + \epsilon_{ij}, \qquad (1)
$$

257 where $PACC5_{ij}$ is the PACC5 scores of subject $i \in [1, N]$ at visit $j \in [1, t]$; $X_{ij} \in \mathbb{R}^{N \times p}$ a 258 matrix of the *p* predictor variables; $\beta \in \mathbb{R}^p$ a vector of fixed-effects regression coefficients; 259 $Z_{ij} \in \mathbb{R}^{N \times q}$ a design matrix for the q random effects; $b_i \in \mathbb{R}^q$ a vector of random effects; and 260 ϵ_{ij} the within-subject measurement errors. The fixed effects structure include clinical group 261 structure measured at baseline and their corresponding interaction with time (t_{ij}) . The fixed 262 effects include age, sex and education taken at baseline.

263 **Structural MRI**

264 Structural MRI scans were acquired at nine German DZNE sites on Siemens MR scanners 265 (including three TIM Trio, four Verio, one Skyra, and one Prisma system). We used T1- 266 weighted MPRAGE images (3D GRAPPA PAT 2, 1 mm³ isotropic, 256×256 , 192 sagittal 267 slices, repetition time 2500 ms, echo time 4.33 ms, inversion time 1100 ms, flip angle 7° , \sim 5 268 min acquisition time) and T2-weighted 3D FLAIR images (GRAPPA PAT factor 2, 1 $mm³$ 269 isotropic, 256×256 , 192 sagittal slices, repetition time 5000 ms, echo time 394 ms, inversion 270 time 1800 ms, ~7 min acquisition time). Standard operating procedures, quality assurance 271 and assessment were provided and supervised by the DZNE imaging network (iNET, 272 Magdeburg) as described in [16]. We computed the mean background intensity as a surrogate 273 measure of image quality and motion artefacts [24,25] and adjusted statistical models for it, 274 as the quality of the scans determine also segmentation performance [26–28].

275 **Biomarker characterisation**

276 Trained study assistants carried out lumbar punctures for 49% of all DELCODE participants. 277 CSF samples were centrifuged, aliquoted and stored at -80°C for retests. Biomarkers known 278 to mirror AD pathology (CSF A β 42 and A β 40) were determined by commercially available 279 kits (V-PLEX Aβ Peptide Panel 1 (6E10) Kit (K15200E)). Each participant was classified as 280 normal (-) or abnormal (+) with regard to amyloid levels based on the Aβ42/40 ratio, 281 independently of their phosphorylated Tau (pTau) status, in line with the ATN classification 282 system. Cut-offs (A β negative: A β 42/40 >0.08; A β positive: A β 42/40 \leq 0.08) were calculated 283 from DELCODE using the Gaussian mixture modelling in the R-package flexmix $(v2.3-15)$ 284 (for details see [16,29]).

285 **WMH segmentation and spatial processing**

286 We processed baseline T1-weighted and FLAIR scans as follows. We performed bias field 287 inhomogeneity correction, skull stripping, and segmentation using the Multi-Brain (MB) 288 toolbox in statistical parametric mapping (SPM) [30]. We segmented grey matter (GM), 289 white matter (WM), and CSF from T1-weighted scans with MB and identified WMH 290 probability maps from FLAIR scans using the Lesion Prediction Algorithm in the Lesion 291 Segmentation Toolbox [31]. We then used MB for normalising tissue classes (and WMH 292 maps) to a DELCODE-specific MB template. We adjusted for local volume changes 293 introduced by the normalisation in GM and WMH probability maps by modulation with 294 Jacobian determinants [30,32]. Finally, we smoothed WMH maps with Gaussian kernels (6 295 mm full width at half maximum). Processing results of all steps were carefully checked 296 visually and statistically using covariance-based tools provided in Computational Anatomy 297 Toolbox 12 (CAT12) [33].

298 **ROI-based processing**

299 We extracted WMH volume from 12 regions of interest (ROI) in cerebral WM, as described 300 in detail in a previous study [11]. In brief, we created ROIs in accordance with the STRIVE 301 criteria [34] and included the four lobes of the brain, four major WM tracks and three 302 sections of the corpus callosum and a global cerebral WM mask. We calculated WMH 303 volumes for each ROI and adjusted for total intracranial volume (TICV). All computations 304 were conducted in the template space.

305 A schematic overview both processing and analysis methods is illustrated in **Figure S1**.

306 **Statistical analyses**

³⁰⁷**Relationship between hypertension and A**β **positivity**

308 We tested for associations between hypertension and Aβ positivity given their potential 309 collinearity [35–38] using the Pearson's Chi-squared test with Yates' continuity correction in 310 the R-package *stats* (v3.6.2).

³¹¹**Effects of hypertension and A**β **positivity on WMH**

312 We hypothesised that a history of hypertension and an abnormal build-up of Aβ relate 313 positively to the volume of WMH, but that both conditions display distinct spatial effects: 314 hypertension on deep and periventricular frontal regions and Aβ on deep and periventricular 315 posterior regions, as discussed in the literature [1,4–9]. We used a 2×2 ANCOVA model in 316 CAT12 to examine the relationship between WMH segmentation maps (outcome) and 317 hypertension and Aβ (factors) at a voxel level. Similarly, to probe the same relationship at an 318 ROI level, we built 2×2 ANCOVA models in R (stats, v3.6.2), one for each region of interest 319 separately. We controlled for covariates and confounders (see '*Covariates, confounders, and* 320 *data transformation*' below).

321 **Effects of WMH on cognitive performance**

322 Our hypothesis was that cognitive performance declined and rates of change in cognition 323 increased as voxel-wise and regional WMH increased, in agreement with previous findings 324 [2,3]. For voxel-based analysis, we used multiple linear regression in CAT12 with WMH 325 segmentation maps as the dependent variable and cognitive performance as the independent 326 variable. Likewise, for each region of interest, we also used multiple linear regression in R 327 (stats, v3.6.2) to probe the relationship between regional WMH volume and cognition. We 328 created different models with memory, executive function, PACC5, and ΔPACC5 as

329 dependent variables. Note that, for studying the effect of baseline WMH on change in 330 cognition, we leveraged summary statistics (ΔPACC5) instead of using a linear mixed effect 331 model to keep the mass univariate analysis efficient [39] and both the voxel- and region-wise 332 analyses consistent. We controlled for hypertension and Aβ positivity in addition to 333 covariates and confounders (see '*Covariates, confounders, and data transformation'* below).

334 **Mediation models**

335 Assuming that long-term exposure to hypertension and Aβ build-up has a negative effect on 336 the integrity of the white matter and that its damage—depicted in the form of regional 337 WMH—impacts cognition negatively, we hypothesise that there is an indirect effect of 338 hypertension and Aβ on cognition that is mediated by WMH volume, in line with theoretical 339 considerations [5,6,40,41] (**Figure 1**). We used the R-package lavaan (v0.6-11) and followed 340 the steps for mediation analysis suggested by Hair *et al*. [42] Significance was assessed using 341 95% confidence intervals generated by bias-corrected bootstrap with 1000 replicates.

342 **Covariates, confounders, and data transformation**

343 We adjusted all models for covariates (age, sex, years of education) and confounders (TICV) 344 and mean background intensity to reduce biases brought in by correlated regressors. To 345 account for collinearity between TICV and sex, we chose "overall mean" as "centring" for 346 TICV and leveraged global scaling for this confounder. We refrained from adjusting our 347 analyses for clinical groups to avoid collinearity issues with Aβ positivity (namely, A^β 348 positivity was more frequent in MCI vs NC and SCD). We log-transformed regional WMH 349 volumes to account for skewness.

350 **Explicit mask**

- 351 We used an explicit mask to constrain the analysis to voxels in which data for at least five
- 352 patients were available.

353 **Correction for multiple comparisons**

- 354 We adjusted *p*-values for multiple comparisons using the false discovery rates (FDR)
- 355 approach to deal with the problem of multiple comparisons.[43]

³⁵⁶**Results**

357 **Sample description**

358 We included baseline data of 375 subjects out of 1079 recruited for DELCODE after quality 359 control and assessing the availability of CSF biomarkers and MRI (Figure S2; median age 360 70.0 [IQR 66.0-74.0] years, 46.9% female, median years of education 13 [IQR 12-17]; 361 European origins). ΔPACC5 was only available for a subset (n=226/375). Demographics and 362 global WMH volumes stratified by hypertension and Aβ positivity are summarised in **Table** ³⁶³**1**. We found no significant association between arterial hypertension and Aβ positivity $364 \quad (X^2 = 2.1302, p=0.1444).$

Group	Subjects n (%)	Age in years Median [IOR]	Female n (%)	Education in years Median [IOR]	WMH volume in ml ^b Median [IOR]
Hypertension	202(53.9)	72 [67, 75]	89(23.7)	13 [12, 17]	1.87 [0.83, 5.83]
Normotension	173(46.1)	69 [64, 72]	87(23.2)	14 [13, 17]	1.19 [0.45, 2.78]
$\mathbf{A}\beta$ positive	132(35.2)	72 [68, 76]	55 (14.7)	13 [12, 17]	2.39 [1.11, 6.32]
$A\beta$ negative	243 (64.8)	68 [65, 73]	121(32.2)	13 [13, 17]	1.16 [0.55, 2.96]

³Global WMH volumes are higher subjects with hypertension vs normotension (W=13744, p<0.001) and Aβ positive vs negative 368 (W=11851, p<0.001); age differences between groups explain, to a certain extent, these outcomes (hypertension vs normotension:
 369 W=13014 p<0.001: Ab positive vs Ab negative: W=10186 p<0.001) W=13014, p<0.001; Aβ positive vs Aβ negative: W=10186, p<0.001) b Unadjusted WMH volumes in ml

n sample size

IQR interquartile range

³⁷³**WMH are associated with both arterial hypertension and A**^β 374 **positivity**

375 We initially investigated WMH in relation to hypertension and Aβ positivity. We observed 376 that the global volume of WMH was a fourth greater in subjects with either a history of 377 hypertension vs normotension (26% [95%-CI 5%, 52%]) or a positive vs negative Aβ status 378 (25% [95%-CI 3%, 52%]) (**Table 2**). Regional variations in the frontal, parietal, and 379 occipital—not temporal—lobes contributed to this outcome; regression coefficients for both 380 hypertension and Aβ positivity were comparable in these three regions (**Table 2**). In posterior 381 regions of the brain, we found that the relationship between WMH and hypertension was 382 clearer than that between WMH and Aβ positivity in the splenium of the corpus callosum 383 (**Figure 2** and **Table 2**); the opposite was true in the optic radiation (**Figure 2** and **Table 2**; 384 peak: between forceps major and inferior fronto-occipital fasciculus).

Table 2. Subjects with hypertension and Aβ **positivity present the largest frontal, parietal, and occipital WMH volumes**^b 385

		Hypertension		$A\beta$ positivity	
	WMH volume ^a	B(SE)	p_{FDR}	B(SE)	p_{FDR}
	Global	0.23(0.09)	0.030	0.22(0.10)	0.044
	Frontal	0.42(0.17)	0.021	0.46(0.18)	0.021
Lobes	Temporal	0.14(0.14)	0.447	0.22(0.15)	0.268
	Occipital	0.50(0.16)	0.003	0.50(0.16)	0.004
	Parietal	0.57(0.18)	0.005	0.56(0.20)	0.008
	Corona radiata	0.45(0.17)	0.020	0.40(0.13)	0.046
Tracts	External capsule	0.21(0.13)	0.171	0.27(0.13)	0.096
	Internal capsule	0.22(0.14)	0.209	0.07(0.15)	0.741
	Optic radiation	0.39(0.18)	0.041	0.74(0.19)	0.001
	Genu	0.23(0.11)	0.087	0.07(0.12)	0.641
Corpus callosum	Body	0.21(0.10)	0.053	0.15(0.10)	0.212
	Splenium	0.36(0.12)	0.005	0.28(0.12)	0.038

³⁸⁶

387 a We log-transformed WMH volumes to deal with skewness

388 b We built multiple linear regression models to examine regional WMH volume (outcome) in relation to hypertension and Aβ positivity 389 (factors)—one for each region of interest separately. We controlled for age, sex, education, mean background intensity, and total intracranial volume. We print p_{FDR} < 0.05 in bold.

391 *pFDR ^p*-values after adjusting for multiple comparisons using FDR

 $\frac{392}{393}$ B regression coefficient
393 SE standard error

SE standard error

394

395 **WMH are negatively associated with cognitive performance and**

396 **outcomes**

397 We then investigated whether cognitive performance and outcomes were associated with 398 WMH (**Figure 3** and **Table 3**). We found a significant association between global WMH 399 volumes and worse baseline cognitive performance and a sharper cognitive decline over the 400 course of three years, regardless of hypertension diagnosis and Aβ positivity (**Table 3**). 401 Evidence for such a connection was present in most regions of interest, except in the external 402 capsule. Such relationships were consistently evident around portions of the anterior thalamic 403 radiation neighbouring the thalamus (**Figure 3**). In frontal and occipital regions, we also saw 404 a significant link between WMH and quicker cognitive deterioration (**Figure 3 -** frontal peak 405 at the level of the genu of the corpus callosum; occipital peak at the level of the forceps major 406 and inferior fronto-occipital longitudinal fasciculus).

		Baseline $(n=375)$	Longitudinal $(n=226)$			
	WMH volume ^a	Memory	Executive	PACC ₅	\triangle PACC5	
		$B(SE); p_{FDR}$	$B(SE); p_{FDR}$	$B(SE); p_{FDR}$	$B(SE); p_{FDR}$	
	Global	$-0.10(0.03); < 0.001$	$-0.08(0.03); 0.005$	$-0.10(0.03); 0.001$	$-0.16(0.05); 0.001$	
Lobes	Frontal	$-0.04(0.05); 0.012$	$-0.03(0.02); 0.028$	$-0.04(0.02); 0.008$	$-0.09(0.03); 0.004$	
	Temporal	$-0.07(0.02); 0.001$	$-0.05(0.02); 0.007$	$-0.07(0.02); < 0.001$	$-0.13(0.04); < 0.001$	
	Occipital	$-0.04(0.02); 0.006$	$-0.02(0.02)$; 0.335	$-0.03(0.02)$; 0.078	$-0.10(0.03); 0.001$	
	Parietal	$-0.04(0.01); 0.002$	$-0.03(0.01); 0.040$	$-0.04(0.01); 0.005$	$-0.06(0.03); 0.025$	
Tracts	Corona radiata	$-0.05(0.01); 0.001$	$-0.04(0.02); 0.008$	$-0.05(0.02); 0.003$	$-0.08(0.03); 0.004$	
	External capsule	$-0.03(0.02)$; 0.142	$-0.00(0.02)$; 0.893	$-0.03(0.02)$; 0.107	$-0.07(0.04)$; 0.103	
	Internal capsule	$-0.05(0.02); 0.004$	$-0.05(0.02); 0.005$	$-0.06(0.02); 0.002$	$-0.08(0.03); 0.016$	
	Optic radiation	$-0.05(0.01); 0.001$	$-0.02(0.01)$; 0.198	$-0.04(0.01); 0.010$	$-0.09(0.03); 0.001$	
callosum Corpus	Genu	$-0.07(0.02); 0.004$	$-0.04(0.02)$; 0.057	$-0.06(0.02); 0.016$	$-0.11(0.04); 0.004$	
	Body	$-0.11(0.03); <0.001$	$-0.10(0.03); < 0.001$	$-0.11(0.03); <0.001$	$-0.16(0.05); 0.001$	
	Splenium	$-0.10(0.02); < 0.001$	$-0.08(0.02); 0.001$	$-0.10(0.02); < 0.001$	$-0.13(0.04); 0.002$	

Table 3. Higher WMH volumes are associated with worse and worsening cognitive performanceb 407

^aWe log-transformed WMH volumes to deal with skewness

 b For each region of interest, we used multiple linear regression to probe the relationship between regional WMH volume and cognitive 411 performance. We created different models with baseline (memory, executive function, and PACC5) and longitudinal (ΔPACC5) cognitive 412 performance as dependent variables. We adjusted for hypertension, Aβ positivity, age, sex, education, mean background intensity, and total intracranial volume. We print p_{FDR} < 0.05 in bold.

414 *pFDR ^p*-values after adjusting for multiple comparisons using FDR

 409
 410
 412
 413
 414
 415

 415 n sample size
 416 B regression of
 417 SE standard e **B** regression coefficient

SE standard error

418

⁴⁰⁸

⁴¹⁹**The effect of A**β **positivity on cognition does not depend on WMH,**

420 **but that of hypertesion does**

421 Our final assessment consisted of determining whether Aβ positivity or hypertension were 422 associated with cognition (**Table 4**). Despite the lack of evidence for a direct association 423 between hypertension and cognitive performance, we found hypertension to be indirectly 424 linked to both worse performance at baseline and a steeper deterioration over the course of 425 three years via splenial WMH (regression coefficient \pm standard error; memory: -0.05 \pm 0.02, ⁴²⁶*pFDR*=0.029; executive: -0.04±0.02, *pFDR*=0.067; PACC5: -0.05±0.02, *pFDR*=0.030; ΔPACC5: 427 -0.09±0.03, p_{FDR} =0.043). On the other hand, the association between A β positivity and 428 baseline and longitudinal cognitive performance (memory: -0.33±0.08, *pFDR*<0.001; 429 executive: -0.21±0.08, *pFDR*<0.001; PACC5: -0.29±0.09, *pFDR*=0.006; ΔPACC5: -0.34±0.04, 430 *p_{FDR}*<0.05) was independent of its association with regional WMH volumes (no grounds for 431 mediation in general, as shown in **Table 2**).

⁴³²**Discussion**

433 Using data from a large multi-site cohort of older adults along the AD spectrum (n=375), we 434 investigated the impact of arterial hypertension and Aβ positivity on WMH and cognition. 435 Our data suggest that (i) both hypertension and Aβ positivity are associated with increased 436 volume of WMH at both voxel and regional levels, (ii) WMH are strongly associated with 437 poor cognitive performance and outcomes, (iii) posterior WMH have a role in the association 438 between hypertension and cognitive performance at baseline and over time, and (iv) the 439 relationship between Aβ positivity and cognition does not depend on WMH. 440 We observed a posterior WMH dominance in Aβ-positive older adults in the predementia 441 stage of the AD continuum. Global and posterior WMH presence and volume were

442 nonetheless the largest when both Aβ retention and hypertension occurred simultaneously 443 and the smallest when none of them did. The posterior white matter could therefore be 444 considered vulnerable to the independent yet interacting and potentiating effects of AD 445 pathology and hypertension-related CSVD. One could thus consider posterior WMH to be a 446 structural correlate that underlies the common observations that vascular disease, in particular 447 hypertension, lowers the threshold for all-cause dementia development in face of pre-existing 448 AD pathology, and vice versa [4–6]. As posterior WMH dominance could also relate to 449 cerebrovascular deposition of $\mathbf{A}\beta$, i.e. cerebral amyloid angiopathy (CAA), a condition that 450 highly overlaps with AD pathology (for review see [44,45]), we visually inspected 451 susceptibility-weighted sequences of all MRIs. Isolated lobar haemorrhagic markers were 452 found in less than 10% (of them 19 were diagnosed with possible and 4 with probable CAA 453 according to the Boston criteria [46,47]) of participants, making a relevant impact of CAA on 454 posterior WMH in our sample highly unlikely.

455 WMH can negatively impact cognitive function, but associations with memory have been 456 less consistent compared to associations with executive function (for review see [48]). With 457 the exception of the external capsule, we found rather substantial evidence for associations 458 between WMH and worse cognitive performance, likewise affecting memory and executive 459 function, and outcomes (**Table 3**). Intriguingly, hypertension was associated with executive, 460 memory, and baseline and longitudinal global cognitive function only via splenial WMH, a 461 white matter structure responsible for cognitive processing and a hub where distinct 462 pathologies impact the neural circuitries interconnecting the temporal and occipital regions of 463 both cerebral hemispheres [7,49–51]. White matter damage in this region, as associated with 464 cardiovascular risk, could be expected to translate to lower cognitive functioning in global 465 cognition but also in discrete domains [7]. In previous studies though, posterior/splenial 466 WMH have been found associated with executive (including attention), but not memory

467 function [7,10]. Differences may arise from WMH quantification methods and/or smaller 468 sample sizes including AD patients only (not individuals with SCD/MCI), in whom largely 469 advanced (medial temporal lobe) AD pathology is the major driver for memory decline, 470 possibly "diluting" concurrent memory effects of posterior WMH.

471 Contrary to our expectations and to strong evidence from large longitudinal population-based 472 studies (for review see [6]), we did not see a direct effect of hypertension effect on cognition 473 but rather an indirect-only effect via splenial WMH. This finding might reflect a selection 474 bias of the DELCODE study: exclusion of individuals with advanced vascular disease, which 475 would likewise result in the exclusion of those with severe and uncontrolled hypertension. 476 This constellation, additionally, explains the somewhat lower prevalence of arterial 477 hypertension (nearly 54% compared to 63%), with a slightly higher number of Aβ positives 478 (35% compared to a range of 17% to 34%) compared to that in population-based cohorts 479 aged over 60 years [52–54]. Our definition of arterial hypertension was based on 480 retrospective screening of medical records for already existing hypertension diagnoses, which 481 might have missed those participants with recently, i.e. newly, diagnosed hypertension after 482 baseline MRI, also contributing to lower prevalence.

483 This study has limitations. First, our imaging results are cross-sectional. While our findings 484 suggest WMH are indeed spatially associated with both hypertension and $\mathbf{A}\beta$ positivity, they 485 do not address causality (e.g. vascular risk first, impaired brain drainage second). 486 Longitudinal analysis of DELCODE imaging data might provide further insights into the 487 influence of lifestyle over time and help disentangle the mixed effects observed in this cross-488 sectional study. Second, our mediation model investigates whether WMH volume can 489 mediate the association between Aβ and hypertension on cognitive function. While this 490 choice was based on a theoretical consideration [5,6,40,41], a model where the AD and 491 CSVD pathologies (here as Aβ accumulation and WMH burden) cyclically contribute to each

492 other would also be feasible [2,5,55]. Third, the study of WMH probability patterns in other 493 cohorts of individuals (e.g. whose origins are other than European; DELCODE participants 494 are predominantly of European origins) with a high vascular but low AD profile or vice versa 495 could be informative on the mechanisms leading to these findings in a more general way. 496 Further, we did not consider WMH patterns, which could be punctuated or confluent, for 497 example, or the clinically established distinction between deep and periventricular WMH.

⁴⁹⁸**Conclusion**

499 Our work points toward a large spatial overlap between the effect of arterial hypertension and 500 Aβ build-up on WMH, with both constellations considered risk factors for white matter 501 damage. At the same time, our work calls into question whether posterior WMH are a core 502 feature related to AD pathology, alternatively suggesting that posterior white matter is 503 vulnerable to both vascular and amyloid pathologies. While the effect of Aβ on cognition 504 would seem rather independent of WMH, posterior WMH seem to play a role in the 505 association between arterial hypertension and poor cognitive performance and outcomes; it 506 could be a promising target to tackle the downstream damage related to the interacting and 507 potentiating effect of multiple pathologies.

⁵⁰⁸**Declarations**

509 **Ethics approval and consent to participate**

510 All participants gave written informed consent before inclusion in the study. DELCODE is 511 retrospectively registered at the German Clinical Trials Register (DRKS00007966, 512 04/05/2015) and was approved by ethical committees and local review boards.

513 **Consent for publication**

514 Not applicable.

515 **Availability of data and materials**

- 516 The datasets used and analysed during the current study are available from the corresponding
- 517 author on reasonable request.

518 **Competing interests**

519 The authors report no competing interests.

520 **Funding**

- 521 This research was supported by the German Center for Neurodegenerative Diseases
- 522 (Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE; reference number BN012)
- 523 and funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG;

524 Project IDs 425899996 and 362321501/RTG 2413 SynAGE). The funding bodies played no

525 role in the design of the study or collection, analysis, or interpretation of data or in writing the 526 manuscript.

527 **Author's contributions**

- 528 Conceptualisation: JB, SS, MW, GZ. Methodology: JB, SS, MW, GZ. Software: JB, GZ.
- 529 Formal analysis: JB. DELCODE study design: ED, AS, and FJ. Image processing: JB, GZ,
- 530 RY, MW. Image analysis and modelling: JB, GZ. Investigation: JB, SS, MW, GZ. Writing
- 531 original draft preparation: JB, SS, MW, GZ. Writing review and editing: All authors.

532 **Acknowledgements**

533 We would like to express our gratitude to all DELCODE participants. We also thank the 534 Max-Delbrück-centrum für Molekulare medizin in der Helmholtz-Gemeinschaft (MDC), 535 Freie Universität Berlin Center for Cognitive neuroscience Berlin (CCNB), Bernstein Center 536 für Computional Neuroscience Berlin, Universitätsmedizin Göttingen Core Facility MR-537 Research Göttingen, Institut für Klinische Radiologie Klinikum der Universität München, 538 and Universitätsklinikum Tübingen MR-Forschungszentrum.

⁵³⁹**References**

540 1. Alber J, Alladi S, Bae HJ, Barton DA, Beckett LA, Bell JM, et al. White matter 541 hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): 542 Knowledge gaps and opportunities. Alzheimer's Dement Transl Res Clin Interv. Elsevier 543 Inc.; 2019;5:107-17.

- 544 2. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical 545 implications. Lancet Neurol. Elsevier Ltd; 2019;18:684–96.
- 546 3. Clancy U, Gilmartin D, Jochems ACC, Knox L, Doubal FN, Wardlaw JM.
- 547 Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic
- 548 review and meta-analysis. The Lancet Psychiatry. Elsevier Ltd; 2021;8:225–36.
- 549 4. Li C, Zhu Y, Ma Y, Hua R, Zhong B, Xie W. Association of Cumulative Blood Pressure
- 550 With Cognitive Decline, Dementia, and Mortality. J Am Coll Cardiol. 2022;79:1321–35.
- 551 5. Ungvari Z, Toth P, Tarantini S, Prodan CI, Sorond F, Merkely B, et al. Hypertension-
- 552 induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol.
- 553 Springer US; 2021;17:639–54.
- 554 6. Palta P, Albert MS, Gottesman RF. Heart health meets cognitive health: evidence on the

25

555 role of blood pressure. Lancet Neurol. Elsevier Ltd; 2021;20:854–67.

- 556 7. Garnier-Crussard A, Bougacha S, Wirth M, Dautricourt S, Sherif S, Landeau B, et al.
- 557 White matter hyperintensity topography in Alzheimer's disease and links to cognition.
- 558 Alzheimer's Dement. 2022;18:422–33.
- 559 8. Pålhaugen L, Sudre CH, Tecelao S, Nakling A, Almdahl IS, Kalheim LF, et al. Brain
- 560 amyloid and vascular risk are related to distinct white matter hyperintensity patterns. J Cereb
- 561 Blood Flow Metab. 2021;41:1162–74.
- 562 9. Desmarais P, Gao AF, Lanctôt K, Rogaeva E, Ramirez J, Herrmann N, et al. White matter
- 563 hyperintensities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer's
- 564 disease. Alzheimer's Res Ther. Alzheimer's Research & Therapy; 2021;13:1–16.
- 565 10. Huynh K, Piguet O, Kwok J, Dobson-Stone C, Halliday GM, Hodges JR, et al. Clinical
- 566 and Biological Correlates of White Matter Hyperintensities in Patients With Behavioral-
- 567 Variant Frontotemporal Dementia and Alzheimer Disease. Neurology. 2021;96:e1743–54.
- 568 11. Gaubert M, Lange C, Garnier-Crussard A, Köbe T, Bougacha S, Gonneaud J, et al.
- 569 Topographic patterns of white matter hyperintensities are associated with multimodal
- 570 neuroimaging biomarkers of Alzheimer's disease. Alzheimer's Res Ther. Alzheimer's
- 571 Research & Therapy; 2021;13:1–11.
- 572 12. Weaver NA, Doeven T, Barkhof F, Biesbroek JM, Groeneveld ON, Kuijf HJ, et al. 573 Cerebral amyloid burden is associated with white matter hyperintensity location in specific
- 574 posterior white matter regions. Neurobiol Aging. Elsevier Inc; 2019;84:225–34.
- 575 13. McAleese KE, Firbank M, Dey M, Colloby SJ, Walker L, Johnson M, et al. Cortical tau
- 576 load is associated with white matter hyperintensities. Acta Neuropathol Commun. Acta 577 Neuropathologica Communications; 2015;3:60.
- 578 14. Englund E. Neuropathology of white matter changes in Alzheimer's disease and vascular
- 579 dementia. Dement Geriatr Cogn Disord. 1998;9:6–12.

- 588 to Establish a Registry on Alzheimer's Disease (CERAD). Part I. Clinical and 589 neuropsychological assessment of Alzheimer's disease. Encycl Clin Neuropsychol. 590 2018;940–4.
- 591 18. Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, et al. 592 Implementation of subjective cognitive decline criteria in research studies. Alzheimer's 593 Dement. 2017;13:296–311.
- 594 19. Jessen F, Amariglio RE, Van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A 595 conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's 596 disease. Alzheimer's Dement. 2014;10:844–52.
- 597 20. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The 598 diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from 599 the National Institute on Aging-Alzheimer's Association workgroups on diagnostic 600 guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7:270–9.
- 601 21. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al.
- 602 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for
- 603 the prevention, detection, evaluation, and management of high blood pressure in adults a
- 604 report of the American College of Cardiology/American Heart Association Task Force on

- 605 Clinical pr. Hypertension. 2018.
- 606 22. Wolfsgruber S, Kleineidam L, Guski J, Polcher A, Frommann I, Roeske S, et al. Minor
- 607 neuropsychological deficits in patients with subjective cognitive decline. Neurology.

608 2020;95:e1134–43.

- 609 23. Papp K V., Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical
- 610 Alzheimer's cognitive composite with semantic processing: The PACC5. Alzheimer's
- 611 Dement Transl Res Clin Interv. Elsevier Inc.; 2017;3:668–77.
- 612 24. Esteban O, Birman D, Schaer M, Koyejo OO, Poldrack RA, Gorgolewski KJ. MRIQC:
- 613 Advancing the automatic prediction of image quality in MRI from unseen sites. PLoS One.
- 614 2017;12:1–21.
- 615 25. Esteban O, Blair RW, Nielson DM, Varada JC, Marrett S, Thomas AG, et al.
- 616 Crowdsourced MRI quality metrics and expert quality annotations for training of humans and
- 617 machines. Sci Data [Internet]. Springer US; 2019;6:1–7. Available from:
- 618 http://dx.doi.org/10.1038/s41597-019-0035-4
- 619 26. Lutti A, Corbin N, Ashburner J, Ziegler G, Phillips C, Kherif F, et al. Restoring statistical
- 620 validity in group analyses of motion- corrupted MRI data. Hum Brain Mapp. 2022;43:1973–
- 621 83.
- 622 27. Alfaro-Almagro F, Jenkinson M, Bangerter NK, Andersson JLR, Griffanti L, Douaud G,
- 623 et al. Image processing and Quality Control for the first 10,000 brain imaging datasets from
- 624 UK Biobank. Neuroimage. 2018;166:400–24.
- 625 28. Bernal J, Valdés-Hernández MDC, Escudero J, Duarte R, Ballerini L, Bastin ME, et al.
- 626 Assessment of perivascular space filtering methods using a three-dimensional computational
- 627 model. Magn Reson Imaging. 2022;93:33–51.
- 628 29. Jessen F, Wolfsgruber S, Kleineindam L, Spottke A, Altenstein S, Bartels C, et al.
- 629 Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory

- 630 centers. Alzheimer's Dement. 2022;1–11.
- 631 30. Brudfors M, Flandin G, Nachev P, Ashburner J. Flexible Bayesian Modelling for
- 632 Nonlinear Image Registration Mikael. Med Image Comput Comput Assist Interv Conf 2020
- 633 Lect Notes Comput Sci. Springer Nature Switzerland AG; 2020. p. 253–63.
- 634 31. Schmidt P, Wink L. LST \Box : A lesion segmentation tool for SPM. 2019.
- 635 32. Ashburner J, Friston KJ. Diffeomorphic registration using geodesic shooting and Gauss-
- 636 Newton optimisation. Neuroimage. Elsevier Inc.; 2011;55:954–67.
- 637 33. Gaser C, Dahnke R. CAT A computational anatomy toolbox for the analysis of
- 638 structural MRI data. [1] C Gaser R Dahnke, "GaserHBM2016," vol 32, no 7, p 7743, 2012.
- 639 2012;32:7743.
- 640 34. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al.
- 641 Neuroimaging standards for research into small vessel disease and its contribution to ageing
- 642 and neurodegeneration. Lancet Neurol. Elsevier Ltd; 2013;12:822–38.
- 643 35. Braun M, Iliff JJ. The impact of neurovascular, blood-brain barrier, and glymphatic
- 644 dysfunction in neurodegenerative and metabolic diseases. 1st ed. Int. Rev. Neurobiol. 645 Elsevier Inc.; 2020.
- 646 36. Brickman AM, Tosto G, Gutierrez J, Andrews H, Gu Y, Narkhede A, et al. An MRI
- 647 measure of degenerative and cerebrovascular pathology in Alzheimer disease. Neurology.
- 648 2018;91:E1402–12.
- 649 37. Cai Z, Wang C, He W, Tu H, Tang Z, Xiao M, et al. Cerebral small vessel disease and 650 Alzheimer's disease. Clin Interv Aging. 2015;10:1695–704.
-
- 651 38. Iturria-Medina Y, Hachinski V, Evans AC. The vascular facet of late-onset Alzheimer's
- 652 disease: An essential factor in a complex multifactorial disorder. Curr Opin Neurol. 653 2017;30:623–9.
- 654 39. Guillaume B, Hua X, Thompson PM, Waldorp L, Nichols TE. Fast and accurate

- 655 modelling of longitudinal and repeated measures neuroimaging data. Neuroimage [Internet].
- 656 Elsevier B.V.; 2014;94:287–302. Available from:
- 657 http://dx.doi.org/10.1016/j.neuroimage.2014.03.029
- 658 40. Harvey A, Montezano AC, Touyz RM. Vascular biology of ageing-Implications in
- 659 hypertension. J Mol Cell Cardiol [Internet]. The Authors; 2015;83:112–21. Available from:
- 660 http://dx.doi.org/10.1016/j.yjmcc.2015.04.011
- 661 41. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease:
- 662 Clinical Insights and Vascular Mechanisms. Can J Cardiol [Internet]. The Authors;
- 663 2018;34:575–84. Available from: https://doi.org/10.1016/j.cjca.2017.12.005
- 664 42. Hair JF, Hult GTM, Ringle CM, Sarstedt M, Danks NP, Ray S. Mediation Analysis.
- 665 Partial Least Squares Struct. Equ. Model. Using R. Springer, Cham; 2021.
- 666 43. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful
- 667 approach to multiple testing. J R Stat Soc Ser B. JSTOR; 1995;289–300.
- 668 44. Charidimou A, Boulouis G, Haley K, Auriel E, Van Etten ES, Fotiadis P, et al. White
- 669 matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy.
- 670 Neurology. 2016;86:505–11.
- 671 45. Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Velow
- 672 SJ. Cerebral amyloid angiopathy and Alzheimer disease one peptide, two pathways
- 673 Steven. Nat Rev Neurol. 2020;16:30–42.
- 674 46. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. Prevalence of
- 675 superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74:1346–
- 676 50.
- 677 47. Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy evolution of the
- 678 Boston criteria. Stroke. 2018;49:491–7.
- 679 48. Roseborough AD, Saad L, Goodman M, Cipriano LE, Hachinski VC, Whitehead SN.

680 White matter hyperintensities and longitudinal cognitive decline in cognitively normal 681 populations and across diagnostic categories: A meta-analysis, systematic review, and 682 recommendations for future study harmonization. Alzheimer's Dement. 2022;1–14.

- 683 49. Altermatt A, Gaetano L, Magon S, Bauer L, Feurer R, Gnahn H, et al. Clinical
- 684 associations of T2-weighted lesion load and lesion location in small vessel disease: Insights
- 685 from a large prospective cohort study. Neuroimage. Elsevier Ltd; 2019;189:727–33.
- 686 50. Kimura Y, Kitagawa K, Oku N, Kajimoto K, Kato H, Tanaka M, et al. Blood Pressure
- 687 Lowering with Valsartan Is Associated with Maintenance of Cerebral Blood Flow and
- 688 Cerebral Perfusion Reserve in Hypertensive Patients with Cerebral Small Vessel Disease. J
- 689 Stroke Cerebrovasc Dis. Elsevier Ltd; 2010;19:85–91.
- 690 51. Yoshita M, Fletcher E, Harvey D, Ortega M, Martinez O, Mungas D, et al. Extent and
- 691 distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology. 692 2006;67:2192–8.
- 693 52. Keuss SE, Coath W, Nicholas JM, Poole T, Barnes J, Cash DM, et al. Associations of β -
- 694 Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal
- 695 Members of the 1946 British Birth Cohort Neurology ® Published Ahead of Print articles
- 696 have been peer reviewed and accepted for publication . This manuscr. Neurology. 2022;1–38.
- 697 53. Krell-Roesch J, Vassilaki M, Mielke MM, Kremers WK, Lowe VJ, Vemuri P, et al.
- 698 Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo
- 699 Clinic Study of Aging. Transl Psychiatry. Springer US; 2019;9.
- 700 54. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension Prevalence
- 701 and Control Among Adults: United States, 2015-2016. NCHS Data Brief. 2017;1–8.
- 702 55. Maillard P, Seshadri S, Beiser A, Himali JJ, Au R, Fletcher E, et al. Effects of systolic
- 703 blood pressure on white-matter integrity in young adults in the Framingham Heart Study: A
- 704 cross-sectional study. Lancet Neurol. 2012;11:1039–47.
	- 31

705

⁷⁰⁶**Figure legends**

707 **Figure 1. Model investigating direct and indirect (via WMH) effects of hypertension and A**β **positivity on** cognition.

709 Here we seek to understand whether subjects with arterial hypertension or β positive status have worse cognitive performance at baseline (baseline memory, executive function, and PACC5 scores) and outcomes over 710 cognitive performance at baseline (baseline memory, executive function, and PACC5 scores) and outcomes over 711 time (\triangle PACC5). Because both the \triangle β and vascular pathologies may exacerbate the formation of WMH a 711 time ($\triangle PACC5$). Because both the Aβ and vascular pathologies may exacerbate the formation of WMH and these, in turn, may also contribute to brain dysfunction and poor cognitive outcomes [5,6,40,41], we also test for These, in turn, may also contribute to brain dysfunction and poor cognitive outcomes [5,6,40,41], we also test for
The an indirect mediating effect of hypertension and AB positivity on cognitive performance via regional WM 713 an indirect mediating effect of hypertension and $\beta \beta$ positivity on cognitive performance via regional WMH volumes. We adjusted such models for age, sex, education, mean background intensity, and TICV, as described 714 volumes. We adjusted such models for age, sex, education, mean background intensity, and TICV, as described in 'Covariates, confounders, and data transformation'. in 'Covariates, confounders, and data transformation'.

716

717 **Figure 2. Posterior WMH probability is associated with both history of arterial hypertension and A**^β positivity.

Analysis. We examined the relationship between WMH segmentation maps (outcome) and arterial hypertension and AB positivity (factors) at a voxel level via 2x2 ANCOVA. We accounted for the effects of age, sex, T20 and Aβ positivity (factors) at a voxel level via 2x2 ANCOVA. We accounted for the effects of age, sex, education, mean background intensity, and total intracranial volume. We used an explicit mask to constrain the ana 721 education, mean background intensity, and total intracranial volume. We used an explicit mask to constrain the The analysis to voxels in which data for at least five patients were available. *Illustration*. Glass brain projections display regions where we found evidence for a link between WMH probability and hypertension and β display regions where we found evidence for a link between WMH probability and hypertension and $\mathsf{A}\beta$ 724 positivity (top and middle rows, respectively). In the bottom row, we coloured regions blue if *T* values for 725 hypertension were greater than for Aβ positivity and gold otherwise. We thresholded contrast maps at 5% and adjusted *p*-values for FDR. *Findings*. Subjects with hypertension had significantly greater WMH volumes 726 adjusted *p*-values for FDR. *Findings*. Subjects with hypertension had significantly greater WMH volumes throughout the whole brain than those with normotension (peak: superior longitudinal fasciculus, $xyz_{MNI} = [32, -16$ throughout the whole brain than those with normotension (peak: superior longitudinal fasciculus, $xyz_{MNI} = [32, -728$ 1, 18], $T = 3.88$, $DoF = [1.0, 367.0]$, $p_{FDR} = 0.015$). Moreover, WMH volume was significantly higher in 728 1, 18], $T = 3.88$, $DoF = [1.0, 367.0]$, $p_{FDR} = 0.015$). Moreover, WMH volume was significantly higher in 729 subjects A_B positivity versus negativity in posterior regions of the brain, particularly in segments of t 729 subjects Aβ positivity versus negativity in posterior regions of the brain, particularly in segments of the forceps major and inferior fronto-occipital fasciculus (*xy_{MNI}* = [30, -58, 4], *T* = 5.20, *DoF* = [1.0, major and inferior fronto-occipital fasciculus (*xyz_{MNI}* = [30, -58, 4], $T = 5.20$, $DoF = [1.0, 367.0]$, $p_{FDR} = 0.001$).

731

732 **Figure 3. WMH volume is associated with worse baseline cognitive performance and accelarated decline** over time.

734 *Analysis.* We used multiple linear regression with WMH segmentation maps as the dependent variable and 735 cognitive performance as the independent variable. We accounted for the effects of hypertension, Aβ positivity, 736 age, sex, education, mean background intensity, and total intracranial volume. We used an explicit mask to
737 constrain the analysis to voxels in which data for at least five patients were available. We thresholded co 737 constrain the analysis to voxels in which data for at least five patients were available. We thresholded contrast maps at 5% and adjusted *p*-values for FDR. *Illustration*. Regression results with memory (top left), e 738 maps at 5% and adjusted *p*-values for FDR. *Illustration*. Regression results with memory (top left), executive function (bottom left), PACC5 (top right), and Δ PACC5 (bottom right) as independent variables. *Findin* 739 function (bottom left), PACC5 (top right), and ΔPACC5 (bottom right) as independent variables. *Findings.* We 740 found WMH to be significantly associated with worse cognitive performance at baseline and sharper decline within a three-year period. Such relationships were consistently evident around portions of the anterior thalami 741 within a three-year period. Such relationships were consistently evident around portions of the anterior thalamic radiation neighbouring the thalamus (memory: $xyz_{MNI} = [-8, -1, 3]$, $T = 7.00$, $DoF = [1.0, 366.0]$, $p_{FDR} =$ radiation neighbouring the thalamus (memory: $xyz_{MNI} = [-8, -1, 3]$, $T = 7.00$, $DoF = [1.0, 366.0]$, $p_{FDR} = 1.44 \times 10^{-5}$; executive: $xyz_{MNI} = [-9, 0, 5]$, $T = 6.74$, $DoF = [1.0, 366.0]$, $p_{FDR} = 2.85 \times 10^{-5}$; PACC5: $xyz_{MNI} = [-8,$ 743 ⁵; executive: *xyz_{MNI}* = [-9, 0, 5], *T* = 6.74, *DoF* = [1.0, 366.0], $p_{FDR} = 2.85 \times 10^{-5}$; PACC5: *xyz_{MNI}* = [-8, 1, 4], *T* = 744 7.20, *DoF* = [1.0, 366.0], $p_{FDR} = 8.43 \times 10^{-6}$; \triangle PACC5: *xyz_{MNI}* = [-7.20, $DoF = [1.0, 366.0]$, $p_{FDR} = 8.43 \times 10^{-6}$; $\Delta PACC5$: $xyz_{MNI} = [-7, 2, 2]$, $T = 4.53$, $DoF = [1.0, 217.0]$, $p_{FDR} = 745$ -5.12×10^{-3}). Frontal and occipital WMH also coincided with a faster cognitive decline (frontal pe 5.12×10⁻³). Frontal and occipital WMH also coincided with a faster cognitive decline (frontal peak at the level of the genu of the corpus callosum: $xy_{ZMNI} = [-1, 23, 4]$, $T = 5.19$, $DoF = [1.0, 217.0]$, $p_{FDR} = 1.37 \times 10^{-3}$ of the genu of the corpus callosum: $xyz_{MNI} = [-1, 23, 4]$, $T = 5.19$, $DoF = [1.0, 217.0]$, $p_{FDR} = 1.37 \times 10^{-3}$; occipital peak at the level of the forceps major and inferior fronto-occipital longitudinal fasciculus: xyz_{MNI} 747 peak at the level of the forceps major and inferior fronto-occipital longitudinal fasciculus: $xyz_{MNI} = [17, -81, 2]$,
748 $T = 4.69$. $DoF = [1.0, 217.0]$. $p_{FDE} = 1.23 \times 10^{-2}$.

 $T = 4.69$, $DoF = [1.0, 217.0]$, $p_{FDR} = 1.23 \times 10^{-2}$.

